表紙
市場調査レポート

PharmaLeaders:世界の医薬品市場のベンチマークレポート - 主要製薬会社の検証と将来分析

PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies

発行 GlobalData 商品コード 317760
出版日 ページ情報 英文 376 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
PharmaLeaders:世界の医薬品市場のベンチマークレポート - 主要製薬会社の検証と将来分析 PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies
出版日: 2014年10月27日 ページ情報: 英文 376 Pages
概要

当レポートでは、世界の医薬品市場のベンチマークについて取り上げ、25の財務指標に対する主要製薬会社30社の競争力について比較し、財務実績、コスト抑制、資本構成、企業活用について検証し、市場影響要因(FDA承認、特許/ジェネリック、規制の変更など)、提携・買収活動、経営戦略なども含めて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 世界の医薬品市場動向

  • 部門の概要
  • 企業価値評価
  • FDAは27の新薬を承認
  • 新たな承認
  • パテントクリフ(特許の崖)
  • オーファンドラッグ
  • 規制ノート

第4章 提携・買収戦略

  • 取引額が急増
  • AbbVieの買収
  • M&A分析
  • ライセンスとパートナーシップ

第5章 財務管理

  • 世界の医薬品市場の競合情勢評価
  • 財務管理:ヒートマップ(比較表)
  • 財務指標

第6章 支出管理

  • 世界の医薬品市場の競合情勢評価
  • 支出管理:ヒートマップ
  • 支出指標

第7章 治療フランチャイズ分析

  • 心血管
  • CNS
  • 糖尿病
  • 胃腸
  • 血液学
  • 免疫学
  • 感染症
  • 腫瘍学
  • 眼科
  • 呼吸器官
  • ワクチン

第8章 地域分析

  • 北米情勢の評価
  • 地域の発展
  • 収益・成長企業
  • 欧州情勢の評価
  • 地域の発展
  • 収益・成長企業
  • アジア太平洋地域情勢の評価
  • 地域の発展
  • 収益・成長企業
  • 日本情勢の評価
  • 収益・成長企業
  • 新興市場情勢の評価
  • 地域の発展
  • 収益・成長企業

第9章 資源管理戦略

  • 人材管理(HCM)
  • 生物製剤の生産能力を拡大
  • 企業活用:ヒートマップ
  • 企業活用メトリクス
  • 資本管理:ヒートマップ
  • 資本構成メトリクス

第10章 将来の見通し

  • 世界の医薬品市場
  • 企業予測

第11章 市場データ

  • 世界の医薬品市場
  • パイプライン分析
  • 企業パイプラインプロファイル
  • 分子タイプ

第12章 付録

図表

目次
Product Code: GDHC005PLR

The Global Pharmaceutical Market Benchmark Report applies GlobalData's proprietary ranking methodology to compare the competitive positions of 30 leading drug companies on 25 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure, and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData's Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

In addition to the financial metrics, this report discusses trends impacting the pharmaceutical marketplace including FDA approvals, patent/generic erosion, regulatory changes, and the impact of the ACA on Rx, along with partnering and acquisition activity, and operations strategy. The report also provides a drill-down analysis identifying the revenue and growth leaders across 4 geographic regions (US, EU, Japan/Asia, and Emerging markets), and 11 therapeutic franchises. Lastly, this report provides GlobalData's outlook on the Global Pharmaceutical market, and each company's future competitive position including six-year forecasts for all 30 companies covered in the report.

Highlights

About the Report

GlobalData identified these 30 leading drug companies to apply its benchmarking methodology providing a foundation for strategic discussion and analysis. GlobalData's coverage examines these companies from a unique company-centric lens - combining financial performance and resources allocation with partnering activity and regional developments to assess a company's overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies' corporate growth.

Key Questions Answered

  • What specific strategies are these drug companies employing to gain market share
  • What drivers accounted for the revenue growth for the company over the past year
  • Which trends will affect the global pharmaceutical market over the next few years
  • Who are the revenue and growth leaders in each therapeutic and geographical area
  • What specific business development activities are taking place, in terms of partnerships or M&A
  • What are the top-selling drugs in each therapeutic franchise and what are their sales forecasts through 2019

Scope

  • This report provides analysis of the key drivers and trends shaping the global pharmaceutical market; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation
  • This report offers a deep dive into the synergies behind partnering and acquisition activity
  • Covers 11 therapeutic franchises; market sizing, growth rates, company share, sales drivers of top drugs, pipeline movements, sales forecasts and product NPVs
  • Assessments of company financials by revenue, margin, expense and capital structure
  • Revenue and growth leaders across 4 geographies; US, EU, Japan/Asia, Emerging markets
  • Firm utilization, efficiency metrics, capital ratios, headcount analytics

Reasons to buy

  • Analyze and track the strategies that these drug companies are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
  • Identifies the important disease areas, types of products, and geographical areas where companies are expanding to ensure their future success
  • Independent source to benchmark your company's performance against a similar peer group to assess areas of strength/weakness

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
    • 2.1.1. Company Covereage
    • 2.1.2. Therapy Franchise Coverage
  • 2.2. Upcoming Reports
  • 2.3. Recently Published Reports
  • 2.4. GlobalData's Benchmarking Methodology
  • 2.5. Benchmark Leader: Pfizer

3. Global Pharmaceutical Market Dynamics

  • 3.1. Sector Overview
    • 3.1.1. Peer Group Growth Rate
    • 3.1.2. Peer Group R&D Spending
  • 3.2. Corporate Valuations
    • 3.2.1. Market Capitalization
    • 3.2.2. Top 30 Pharma Valuations Compared Against the S&P500
  • 3.3. FDA Approved 27 Novel New Drugs in 2013
    • 3.3.1. From 2004 through 2013, CDER has Averaged 26 NME Approvals per Year
    • 3.3.2. Multiple Pathways for Accelerating Drug Approvals
    • 3.3.3. CDER Met or Exceeded PDUFA Goal Dates for All 27 NMEs Approved in 2013
    • 3.3.4. Drug Approvals Signify a Commercial Focus on High Growth Therapeutic Areas
    • 3.3.5. List of Approved NMEs in 2013
    • 3.3.6. GlobalData Sales Forecast for 2013 Approved Drugs
  • 3.4. New Approvals Drive Much Needed Value in the Pharmaceutical Market
    • 3.4.1. Exceptional Uptake of Sovaldi and Tecfidera Paves the way for New Optimism in Pharma
  • 3.5. Patent Cliff to Erode $65B in Sales by 2019
    • 3.5.1. Top 50 Patent Expiries
  • 3.6. Orphan Drugs: No Longer a Rare Opportunity
  • 3.7. Regulatory Notes
    • 3.7.1. FDA Issues Draft Guidance on Determination of Product Exclusivity for Biologics
    • 3.7.2. Federal Appeals Court Rules FDA Has Authority to Regulate Stem Cells

4. Collaboration and Acquisition Strategies

  • 4.1. Deal Values Soar Due to Shire Acquisition
  • 4.2. Deep Dive: AbbVie Acquires Shire as the Threat of Humira Biosimilars Looms
    • 4.2.1. Deal Terms
    • 4.2.2. Combined Entity Holds Promise for AbbVie
    • 4.2.3. Tax Inversion Impact on Humira Cash Flow
    • 4.2.4. Shire Purchase Softens the Impact of AbbVie's Maturing Portfolio
    • 4.2.5. Acquisition Reduces AbbVie's Dependency on Humira Sales
    • 4.2.6. Shire Sales Forecasts and Portfolio Valuation
  • 4.3. M&A Analysis
    • 4.3.1. Roche Makes Respiratory Play with InterMune Buy
    • 4.3.2. AstraZeneca Rejects Pfizer's Takeover Bid
    • 4.3.3. Teva Acquires Novel Migraine Prophylaxis Treatment
    • 4.3.4. Valeant's Business Model Not Conducive for Allergan
    • 4.3.5. Shire Boosts Rare Disease Pipeline
    • 4.3.6. BMS Acquires Neuro Firm iPierian
    • 4.3.7. Amgen Dives into Multiple Myeloma Market, Gains Rights to Kyprolis
    • 4.3.8. Bayer Buys-Out Cancer Partner Algeta, Purchases Conceptus
    • 4.3.9. AZ Strengthens Respiratory Portfolio
    • 4.3.10. J&J Pays Big for Aragon's Lead Pipeline Candidate
    • 4.3.11. Allergan Enhances Leadership Position in Neurology
    • 4.3.12. Astex Deal Might Stem the Bleeding for Otsuka
    • 4.3.13. Select Generic M&As
  • 4.4. Licensing and Partnerships
    • 4.4.1. BMS on a Shopping Spree for Cancer Immunotherapies
    • 4.4.2. Bayer Scoops-Up Orion's Phase III Prostate Cancer Drug
    • 4.4.3. GSK Signs Deal with Adaptimmune to Develop T-cells
    • 4.4.4. Celgene: A Licensing Machine
    • 4.4.5. Novartis Pens Deal for Ophthotech's Wet-AMD Treatment Fovista
    • 4.4.6. Merck Inks Potential Mega Deal with Ablynx, Sells-Off Eye Drugs
    • 4.4.7. Biogen Forges Preclinical Alzheimer's Pact with Proteostasis
    • 4.4.8. Roche Turns on the Switch in Epigenetics

5. Financial Management

  • 5.1. Global Pharmaceutical Market Competitive Landscape Assessment
    • 5.1.1. The Drug Sector Began to Show Signs of Stabilization in 2013
  • 5.2. Financial Management: Heat Map
    • 5.2.1. Gilead was the Financial Management Leader in 2013
  • 5.3. Financial Performance Metrics
    • 5.3.1. Revenue
    • 5.3.2. Revenue Growth YtY
    • 5.3.3. Operating Income
    • 5.3.4. Operating Income Growth YtY
    • 5.3.5. Operating Margin
    • 5.3.6. Operating Income per FTE
    • 5.3.7. Net Margin

6. Expense Management

  • 6.1. Global Pharmaceutical Market Competitive Landscape Assessment
    • 6.1.1. Consistent Cost Structures Give Drugmakers Margin Stability
    • 6.1.2. Eisai Pushes Arena's Belviq with More Reps and Ad Spending
  • 6.2. Expense Management: Heat Map
    • 6.2.1. Eisai was the Expense Management Leader in 2013
  • 6.3. Expense Performance Metrics
    • 6.3.1. S,G&A Spending
    • 6.3.2. S,G&A Spending as a Percentage of Revenue
    • 6.3.3. S&M Spending
    • 6.3.4. R&D Spending
    • 6.3.5. R&D Spending Growth
    • 6.3.6. R&D Spending as a Percentage of Revenue

7. Therapy Franchise Analysis

  • 7.1. Cardiovascular
    • 7.1.1. Commercial Landscape
    • 7.1.2. Pipeline Highlights
  • 7.2. CNS
    • 7.2.1. Commercial Landscape
    • 7.2.2. Pipeline Highlights
  • 7.3. Diabetes
    • 7.3.1. Commercial Landscape
    • 7.3.2. Pipeline Highlights
  • 7.4. Gastrointestinal
    • 7.4.1. Commercial Landscape
    • 7.4.2. Pipeline Highlights
  • 7.5. Hematology
    • 7.5.1. Commercial Landscape
    • 7.5.2. Pipeline Highlights
  • 7.6. Immunology
    • 7.6.1. Commercial Landscape
    • 7.6.2. Pipeline Highlights
  • 7.7. Infectious Disease
    • 7.7.1. Commercial Landscape
    • 7.7.2. Pipeline Highlights
  • 7.8. Oncology
    • 7.8.1. Commercial Landscape
    • 7.8.2. Pipeline Highlights
  • 7.9. Ophthalmology
    • 7.9.1. Commercial Landscape
    • 7.9.2. Pipeline Highlights
  • 7.10. Respiratory
    • 7.10.1. Commercial Landscape
    • 7.10.2. Pipeline Highlights
  • 7.11. Vaccines
    • 7.11.1. Commercial Landscape
    • 7.11.2. Pipeline Highlights

8. Regional Analysis

  • 8.1. North America Landscape Assessment
    • 8.1.1. Growth Driven by Biotechs and Specialty Pharma
  • 8.2. Regional Developments
    • 8.2.1. Gilead's Price of Sovaldi May be a Pill too Tough to Swallow
    • 8.2.2. States' Take Efforts into Their Own Hands to Limit the Influx of Opioids
  • 8.3. Revenue and Growth Leaders
    • 8.3.1. Revenue
    • 8.3.2. Revenue Growth YtY
  • 8.4. Europe Landscape Assessment
    • 8.4.1. AstraZeneca Pulls Down EU Market
  • 8.5. Regional Developments
    • 8.5.1. Merck KGaA Targets Italian Production Site for Investment
    • 8.5.2. Pfizer Partners with UK Academics to Develop Rare Disease Drugs
    • 8.5.3. Bayer's Eylea Hits Road Block in Germany
  • 8.6. Revenue & Growth Leaders
    • 8.6.1. Revenue
    • 8.6.2. Revenue Growth YtY
  • 8.7. Asia-Pacific Landscape Assessment
    • 8.7.1. Astellas Pharma was the Growth Leader in Asia
  • 8.8. Regional Developments
    • 8.8.1. China Targets Big Pharma in Corruption Investigation
    • 8.8.2. UCB Secures Asian Marketing Rights to Biogen's MS Drugs
    • 8.8.3. Merck KGaA Targets China with Allergy and Diabetes Plants
  • 8.9. Revenue & Growth Leaders
    • 8.9.1. Revenue
    • 8.9.2. Revenue Growth YtY
  • 8.10. Japan Landscape Assessment
    • 8.10.1. Daiichi Sankyo Trumps its Domestic Rivals
  • 8.11. Revenue & Growth Leaders
    • 8.11.1. Revenue
    • 8.11.2. Revenue Growth YtY
  • 8.12. Emerging Markets Landscape Assessment
    • 8.12.1. Differences in Regulatory and Commercialization Pathways Makes BRICs More Difficult than Previously Thought
  • 8.13. Regional Developments
    • 8.13.1. India to Receive Deep Discount on Sovaldi Price
    • 8.13.2. Pharma Furious Over Compulsory Licensing in India
    • 8.13.3. India Commits $500M to Doubling its Regulatory Force
    • 8.13.4. Abbott Grows Footprint in Latin America with CFR Buy
    • 8.13.5. GSK to Freeze Vaccine Prices for Developing Countries
    • 8.13.6. Drug Manufacturers Look to the Middle East for Untapped Opportunities
  • 8.14. Revenue & Growth Leaders
    • 8.14.1. Revenue
    • 8.14.2. Revenue Growth YtY

9. Resource Management Strategies

  • 9.1. Human Capital Management
    • 9.1.1. Headcount Analysis
    • 9.1.2. Layoffs in 2013
  • 9.2. Drugmakers Expand Manufacturing Capacity for Biologics
    • 9.2.1. Roche Ramps up Production in Switzerland
    • 9.2.2. Drugmakers Advance into Asia to Grab Share
    • 9.2.3. Eisai Plans Major Sales Push in Russian Market
    • 9.2.4. Daiichi Unloads Ranbaxy Problems to Sun Pharma
  • 9.3. Firm Utilization: Heat Map
    • 9.3.1. Pfizer was the Firm Utilization Leader in 2013
  • 9.4. Firm Utilization Metrics
    • 9.4.1. Headcount Growth YtY
    • 9.4.2. Revenue per Employee
    • 9.4.3. R&D Expense per R&D Employee
    • 9.4.4. G&A Expense per G&A Employee
    • 9.4.5. S&M Expense per S&M Employee
  • 9.5. Capital Management: Heat Map
    • 9.5.1. Allergan was the Capital Management Leader due to its Higher Liquidity
  • 9.6. Capital Structure Metrics
    • 9.6.1. Debt/Equity
    • 9.6.2. Sales/Assets
    • 9.6.3. Return on Capital Employed
    • 9.6.4. Cash Ratio
    • 9.6.5. Current Ratio
    • 9.6.6. Quick Ratio

10. Future Outlook

  • 10.1. Global Pharmaceutical Market
  • 10.2. Company Forecasts

11. Market Data

  • 11.1. Global Pharmaceutical Market
    • 11.1.1. Pharmaceutical Revenue Forecast for 128 Leading Companies
  • 11.2. Pipeline Analysis
    • 11.2.1. Forecasts & Valuations
  • 11.3. Company Pipeline Profiles
  • 11.4. Molecule Type
    • 11.4.1. Biologics Versus Small Molecules

12. Appendix

  • 12.1. Research Methodology
    • 12.1.1. Coverage
    • 12.1.2. Secondary Research
  • 12.2. About the Author
    • 12.2.1. Adam Dion, Industry Analyst
  • 12.3. Director, Healthcare Industry Dynamics
  • 12.4. Global Head of Healthcare
  • 12.5. About the Industry Dynamics Team
  • 12.6. About GlobalData
  • 12.7. Disclosure Information
  • 12.8. Disclaimer

List of Tables

  • Table 1: GlobalData Benchmark Rankings, Global Pharmaceutical Market, 2013
  • Table 2: GlobalData Benchmark Rankings (cont'd), Global Pharmaceutical Market, 2013
  • Table 3: List of Approved New Molecular Entities, 2013
  • Table 4: Sales Forecast ($m) for Recently Approved Drugs, 2013
  • Table 5: Top 50 Patent Expiries, Sales ($m), 2013-2019
  • Table 6: Financial Management Composite Scores, 2013
  • Table 7: Expense Management Composite Scores, S,G&A, 2013
  • Table 8: Expense Management Composite Scores, R&D, 2013
  • Table 9: Therapy Franchise Market Outlook ($m) and Compound Annual Growth Rate, 2010-2019
  • Table 10: Top Largest Layoffs, 2013
  • Table 11: Firm Utilization Composite Scores, 2013
  • Table 12: Firm Utilization Composite Scores (cont'd), 2013
  • Table 13: Capital Management Composite Scores, Debt & Profitability Ratios, 2013
  • Table 14: Capital Management Composite Scores, Debt & Profitability Ratios, 2013
  • Table 15: Capital Management Composite Scores, Liquidity Ratios, 2013
  • Table 16: Capital Management Composite Scores, Liquidity Ratios, 2013

List of Figures

  • Figure 1: Combined Peer Group Revenue ($m) and Average Operating Margin, 2010-2013
  • Figure 2: Combined Peer Group R&D Spend ($m), 2010-2013
  • Figure 3: Total Market Capitalization ($bn), 2010-2014
  • Figure 4: Market Capitalization ($bn) by Company, 2014
  • Figure 5: Change in Market Capitalization ($bn) by Company
  • Figure 6: Top 30 Pharmaceutical Companies Valuation vs. S&P500
  • Figure 7: Number of NME Approvals and Applications Filed, 2004-2013
  • Figure 8: Percentage of NMEs by Approval Pathway, 2011-2013
  • Figure 9: Percentage of NMEs Approved First in the US and on First Cycle of Review, 2011-2013
  • Figure 10: Combined Revenue Projections of 2013 FDA Approvals vs. 2012 FDA Approvals ($m), 2012-2019
  • Figure 11: First Full-Year Sales ($m) of Major Product Launches by Year, 2009-2013
  • Figure 12: Revenue Projections for 2013 FDA Approvals ($m), 2013-2019
  • Figure 13: Patent Cliff Sales ($m) Erosion, 2013-2019
  • Figure 14: Percentage of Biosimilar Exposure on Company Revenues, 2013
  • Figure 15: Orphan Peer Group ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 16: Leading Orphan Drug Sales ($m), 2013 vs. 2019
  • Figure 17: Global Pharmaceutical Market, Total Deals and Deal Values ($m), 2009-2014
  • Figure 18: Number of M&A Deals and Deal Values ($m), 2009-2014
  • Figure 19: Number of Licensing Deals and Deal Values ($m), 2009-2014
  • Figure 20: M&A Deal Values ($m) by Company, 2004-2014
  • Figure 21: Licensing Deal Values ($m) by Company, 2004-2014
  • Figure 22: Projected Total Revenues ($m) for AbbVie/Shire Merger, 2014-2019
  • Figure 23: Tax Savings Impact of Shire Merger on Humira Cash Flow ($m), 2014-2029
  • Figure 24: Humira as a Percentage (%) of Total Sales Pre-and Post-Acquisition of Shire, 2014-2019
  • Figure 25: Potential Threat of Biosimilars on Humira Cash Flow ($m), 2014-2029
  • Figure 26: Combined Six-Year Forecast Revenues ($m) Across Shire's Portfolio
  • Figure 27: Shire Leading Assets by Net Present Value ($m)
  • Figure 28: InterMune, Esbriet, Sales Forecast ($m), 2013-2019
  • Figure 29: Global Pharmaceutical Market Landscape Assessment - FY2013 Revenue Growth vs. Operating Margin
  • Figure 30: Revenue ($m) by Company, 2013
  • Figure 31: Revenue Growth by Company, 2013
  • Figure 32: Operating Income ($m) by Company, 2013
  • Figure 33: Operating Income Growth by Company, 2013
  • Figure 34: Operating Margin by Company, 2013
  • Figure 35: Operating Income per Employee, 2013
  • Figure 36: Net Margin by Company, 2013
  • Figure 37: Global Pharmaceutical Market Landscape Assessment - FY2013 S,G&A Expense vs. R&D Expense
  • Figure 38: S,G&A Spending ($m) by Company, 2013
  • Figure 39: S,G&A Spend as a Percentage of Revenue by Company, 2013
  • Figure 40: Sales and Marketing Spending ($m) by Company, 2013
  • Figure 41: R&D Spending ($m) by Company, 2013
  • Figure 42: R&D Spending Growth by Company, 2013
  • Figure 43: R&D Spending as a Percentage of Revenue by Company, 2013
  • Figure 44: Peer Group Rx Sales ($m) & Compound Annual Growth Rate, 2010-2019
  • Figure 45: Cardiovascular Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 46: Cardiovascular Market Share, 2013
  • Figure 47: Cardiovascular Market Share, 2010
  • Figure 48: Cardiovascular Drug Sales ($m), 2013 vs. 2019
  • Figure 49: CNS Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 50: CNS Market Share, 2013
  • Figure 51: CNS Market Share, 2010
  • Figure 52: CNS Drug Sales ($m), 2006-2019
  • Figure 53: CNS Drug Sales ($m), 2013 vs. 2019
  • Figure 54: Diabetes Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 55: Diabetes Market Share, 2013
  • Figure 56: Diabetes Market Share, 2010
  • Figure 57: Diabetes Drug Sales ($m), 2013 vs. 2019
  • Figure 58: Gastrointestinal Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 59: Gastrointestinal Market Share, 2013
  • Figure 60: Gastrointestinal Market Share, 2010
  • Figure 61: Gastrointestinal Drug Sales ($m), 2013 vs. 2019
  • Figure 62: Hematology Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 63: Hematology Market Share, 2013
  • Figure 64: Hematology Market Share, 2010
  • Figure 65: Hematology Drug Sales ($m), 2013 vs. 2019
  • Figure 66: Immunology Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 67: Immunology Market Share, 2013
  • Figure 68: Immunology Market Share, 2010
  • Figure 69: Immunology Drug Sales ($m), 2006-2019
  • Figure 70: Immunology Drug Sales ($m), 2013 vs. 2019
  • Figure 71: Infectious Diseases Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 72: Infectious Disease Market Share, 2013
  • Figure 73: Infectious Disease Market Share, 2010
  • Figure 74: Infectious Disease Drug Sales ($m), 2013 vs. 2019
  • Figure 75: Oncology Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 76: Oncology Market Share, 2013
  • Figure 77: Revlimid vs. MabThera/Rituxan Sales ($m), 2006-2019
  • Figure 78: Oncology Market Share, 2010
  • Figure 79: Oncology Drug Sales ($m), 2013 vs. 2019
  • Figure 80: Ophthalmology Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 81: Ophthalmology Market Share, 2013
  • Figure 82: Eylea vs. Lucentis Sales ($m), 2007-2019
  • Figure 83: Ophthalmology Market Share, 2010
  • Figure 84: Ophthalmology Drug Sales ($m), 2013 vs. 2019
  • Figure 85: Respiratory Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 86: Respiratory Market Share, 2013
  • Figure 87: Respiratory Market Share, 2010
  • Figure 88: Spiriva vs. Advair Sales ($m), 2006-2019
  • Figure 89: Respiratory Drug Sales ($m), 2013 vs. 2019
  • Figure 90: Vaccine Market Size ($m) and Compound Annual Growth Rate, 2010-2019
  • Figure 91: Vaccines Market Share, 2013
  • Figure 92: Vaccines Market Share, 2010
  • Figure 93: Vaccine Drug Sales ($m), 2013 vs. 2019
  • Figure 94: North America Landscape Assessment, 2013
  • Figure 95: North America Landscape Assessment (cont'd), 2013
  • Figure 96: North America Revenue ($m) by Company, 2013
  • Figure 97: North America Revenue Growth by Company, 2013
  • Figure 98: Europe Landscape Assessment, 2013
  • Figure 99: Europe Landscape Assessment (cont'd), 2013
  • Figure 100: Europe Revenue ($m) by Company, 2013
  • Figure 101: Europe Revenue Growth by Company, 2013
  • Figure 102: APAC Landscape Assessment, 2013
  • Figure 103: APAC Landscape Assessment (cont'd), 2013
  • Figure 104: APAC Revenue ($m) by Company, 2013
  • Figure 105: APAC Revenue Growth by Company, 2013
  • Figure 106: Japan Landscape Assessment, 2013
  • Figure 107: Japan Revenue ($m) by Company, 2013
  • Figure 108: Japan Revenue Growth by Company, 2013
  • Figure 109: Emerging Markets Landscape Assessment, 2013
  • Figure 110: Emerging Markets Landscape Assessment (cont'd), 2013
  • Figure 111: Emerging Markets Revenue ($m) by Company, 2013
  • Figure 112: Emerging Markets Revenue Growth by Company, 2013
  • Figure 113: Peer Group Headcount, Total, 2010-2013
  • Figure 114: Headcount by Company, 2013 vs. 2012
  • Figure 115: Peer Group Headcount, R&D, 2010-2013
  • Figure 116: R&D Headcount by Company, 2013 vs. 2012
  • Figure 117: Headcount Growth by Company, 2013
  • Figure 118: Revenue per Employee (In $ Thousands) by Company, 2013
  • Figure 119: R&D Expense per R&D Employee (In $ Thousands) by Company, 2013
  • Figure 120: G&A Expense per G&A Employee (In $ Thousands) by Company, 2012
  • Figure 121: S&M Expense per S&M Employee (In $ Thousands) by Company, 2013
  • Figure 122: Debt to Equity Ratio by Company, 2013
  • Figure 123: Sales to Assets Ratio by Company, 2013
  • Figure 124: Return on Capital Employed Ratio by Company, 2013
  • Figure 125: Cash Ratio by Company, 2013
  • Figure 126: Current Ratio by Company, 2013
  • Figure 127: Quick Ratio by Company, 2013
  • Figure 128: Pharmaceutical Benchmark Peer Group, Global Market Forecast, ($m), 2013-2019
  • Figure 129: Pharmaceutical Revenue Forecast ($m) by Peer Group, 2013 vs. 2019
  • Figure 130: Marketed and Pipeline Sales ($m) by Company, 2013
  • Figure 131: Percentage of Total Revenues, Pharma vs. Non-Pharma, 2013
  • Figure 132: Total Revenue ($m) Forecasts by Company, 2013 vs. 2019
  • Figure 133: Prescription Drug Sales ($m) Forecasts by Company, 2013 vs. 2019
  • Figure 134: Global Pharmaceutical Market Forecast ($m), 2013-2019
  • Figure 135: Marketed Product and Pipeline Sales Contributions ($m), 2019
  • Figure 136: Total Pharmaceutical Pipeline Revenue ($m), 2013-2019
  • Figure 137: Marketed vs. Pipeline Sales Contribution ($m), 2019
  • Figure 138: Pipeline Net Present Value ($m) by Company
  • Figure 139: Pipeline Sales ($m) by Company, 2019
  • Figure 140: AbbVie, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 141: Allergan, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 142: Amgen, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 143: Astellas, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 144: AstraZeneca, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 145: Baxter, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 146: Bayer, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 147: Biogen Idec, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 148: Boehringer Ingelheim, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 149: BMS, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 150: Celgene, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 151: CSL, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 152: Daiichi Sankyo, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 153: Eisai, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 154: Eli Lilly, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 155: F. H. La-Roche, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 156: Gilead, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 157: GSK, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 158: Johnson & Johnson, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 159: Merck, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 160: Merck KGaA, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 161: Novartis, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 162: Novo Nordisk, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 163: Otsuka, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 164: Pfizer, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 165: Sanofi, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 166: Shire, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 167: Takeda, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 168: Teva, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 169: UCB Pharma, Number of Clinical Trials, Phase and Therapy Area, 2014
  • Figure 170: Revenue Forecast ($m) by Molecule Type, Small Molecule vs. Biologics, 2019
  • Figure 171: Biologics Sales ($m) by Company, 2013
  • Figure 172: Percentage of Total Revenues, Biologics vs. Small Molecules, 2013
  • Figure 173: Biologics and Small Molecule Sales ($m) by Company, 2013
  • Figure 174: Net Present Value of Biologics Portfolio ($m) by Company, 2013
Back to Top